



PEPTECH
LIMITED

31 January 2007

Peptech Limited
ABN 98 002 951 877

19-25 Khartoum Rd
Macquarie Park NSW 2113 Australia

Locked Bag 2053
North Ryde NSW 1670 Australia

Telephone +61 2 9870 8788
Facsimile +61 2 9870 8786

ASX / MEDIA ANNOUNCEMENT

Peptech launches next generation Suprelorin12[®].

Peptech Animal Health Pty Limited (PAH), a wholly-owned subsidiary of Australian biotechnology company Peptech Limited (ASX:PTD), today announced the Australian launch of its advanced canine contraceptive, Suprelorin12[®].

Suprelorin12[®], the next generation of PAH's Suprelorin[®], provides a safe and effective fertility-control alternative to surgical castration in male dogs and has a 12-month duration of action, extending the benefits of the original Suprelorin[®], which is active for six months.

PAH is currently pursuing registration applications with regulatory authorities in both the US and Europe for Suprelorin[®]. Suprelorin[®] is expected to generate revenue from the lucrative European market during 2007.

Peptech Animal Health General Manager Dr Paul Schober said, "PAH's demonstrated excellence in animal health technology has helped earn the company strong recognition amongst its veterinary customers around Australia.

"With the continued increase in Suprelorin[®] sales in Australia over the last year, we are confident that the increased convenience provided by the 12-month product will generate greater market penetration," said Dr Schober.

"Suprelorin[®] sales in Australia increased by 20% over the last six months to December 2006 compared with the previous six months and by over 50% from the previous year.

"First orders for the new 12-month product have already been received. Peptech is now leveraging its exciting technology to firmly establish a presence in the lucrative US and European markets and position the Suprelorin technologies as potential blockbuster animal health products," he added.

ENDS

Further information:

Dr Paul Schober
General Manager
Peptech Animal Health Pty Limited
Phone: 02 9870 8788

Released by:

Ms Jodie Leckenby
Consultant
Phillips Group
Mobile: 0403 783 932

About Peptech:

Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. The company is positioned to become a globally recognised leader in biopharmaceutical development.

For further information: www.peptech.com

About Suprelorin[®] and Suprelorin12[®]

The active agent in both products is a synthetic analogue of a naturally occurring hormone (LHRH). When this analogue is given over a sustained period of time the chemical message to produce steroid hormones from the pituitary gland to the gonads is impaired. The drug delivery platform for Suprelorin[®] and Suprelorin12[®] - a subcutaneous, slow-release, lecithin-based, biocompatible implant - is unique in the market and has wide potential applications. Peptech is a world leader in this type of slow-release implantable technology.

Trials of up to five consecutive treatments over three years of Suprelorin[®] have shown that fertility returns when treatment is stopped, making the treatment reversible, which is a major bonus for breeders.

Because they halt the production of testosterone, Suprelorin[®] and Suprelorin12[®] achieve reversible sterilisation as well as similar behavioural improvements seen with castration. The implants have also been shown to be effective in treating benign prostrate hyperplasia, an enlargement of the prostate gland commonly seen in older entire dogs that can cause numerous clinical signs varying in severity.

Suprelorin[®] (as a 2.3x6mm cylindrical dose) and Suprelorin12[®] (2.3x12mm) are inserted between the dog's shoulders. The disposable implanter is no larger than that used to implant microchips in dogs and is a highly cost-effective way to deliver the drug. No anaesthetic is required and there is none of the discomfort, recovery or potential risks that would be associated with surgery.

Both Suprelorin[®] and Suprelorin12[®] have potential beyond the reversible sterilisation of male dogs, to improve the health of many species of animals on a number of fronts.

Recent studies show that both products are also effective in treating incontinence in spayed bitches. This gives dog owners a convenient long-term treatment option over the current therapies that not only require frequent medicating but can be associated with dangerous side-effects.

Suprelorin[®] and Suprelorin12[®] are currently being used in wildlife parks and zoos for population control on a number of different species including lions, cheetahs, monkeys, dolphins, seals and other mammals.

Patent applications are being expanded to cover repeat usage, use in females, use for other indications and in other animal species.

Further information is available on Peptech's website: www.peptech.com